CONTEXT: Previous studies report that increased expression of cyclooxygenase 2 (COX-2) correlates with poor clinical outcome in several malignancies, including non- small cell lung carcinoma (NSCLC). Cyclooxygenase 2 inhibitors have been reported to effectively inhibit carcinogenesis in colon cancer experimental models. OBJECTIVE: We examined COX-2 expression in 259 cases of NSCLC to evaluate its prognostic significance. DESIGN: Sections of NSCLC from patients with a median 5-year follow-up were immunostained with COX-2 monoclonal antibody (1:150) using the Dako mouse EnVision;pl system. Extent of COX-2 expression in neoplastic cells was recorded as follows: 0, 0% to 10% of cells positive; 1, 11% to 33% positive; 2, 34% to 66% positive; and 3, more than 66% positive. Intensity was scored as either increased (+) or not increased (-), compared to internal control smooth muscle and endothelial cells. Kaplan-Meier analysis was used to assess the relationship between survival and COX-2 expression, using the log-rank test for statistical significance. RESULTS: No relationship was found between the extent and/or the intensity of COX-2 expression and patient survival when the entire cohort was considered. However, when separately analyzed according to disease stage and intensity of COX-2 expression, a significant relationship (P = .03) between increased COX-2 expression and shortened patient survival was found only in patients with stage I and II NSCLC. CONCLUSIONS: To our knowledge, this is the largest series of NSCLCs in which COX-2 has been investigated as a prognostic marker. The findings in this large series support previous studies of smaller cohorts that reported that increased COX-2 expression predicts poor outcome in patients with early-stage NSCLC.
CONTEXT: Previous studies report that increased expression of cyclooxygenase 2 (COX-2) correlates with poor clinical outcome in several malignancies, including non- small cell lung carcinoma (NSCLC). Cyclooxygenase 2 inhibitors have been reported to effectively inhibit carcinogenesis in colon cancer experimental models. OBJECTIVE: We examined COX-2 expression in 259 cases of NSCLC to evaluate its prognostic significance. DESIGN: Sections of NSCLC from patients with a median 5-year follow-up were immunostained with COX-2 monoclonal antibody (1:150) using the Dako mouse EnVision;pl system. Extent of COX-2 expression in neoplastic cells was recorded as follows: 0, 0% to 10% of cells positive; 1, 11% to 33% positive; 2, 34% to 66% positive; and 3, more than 66% positive. Intensity was scored as either increased (+) or not increased (-), compared to internal control smooth muscle and endothelial cells. Kaplan-Meier analysis was used to assess the relationship between survival and COX-2 expression, using the log-rank test for statistical significance. RESULTS: No relationship was found between the extent and/or the intensity of COX-2 expression and patient survival when the entire cohort was considered. However, when separately analyzed according to disease stage and intensity of COX-2 expression, a significant relationship (P = .03) between increased COX-2 expression and shortened patient survival was found only in patients with stage I and II NSCLC. CONCLUSIONS: To our knowledge, this is the largest series of NSCLCs in which COX-2 has been investigated as a prognostic marker. The findings in this large series support previous studies of smaller cohorts that reported that increased COX-2 expression predicts poor outcome in patients with early-stage NSCLC.
Authors: Imtiyaz A Bhat; Roohi Rasool; Iqbal Qasim; Khalid Z Masoodi; Shabeer A Paul; Bashir A Bhat; Farooq A Ganaie; Sheikh A Aziz; Zafar A Shah Journal: Tumour Biol Date: 2014-08-12
Authors: Alison L Van Dyke; Michele L Cote; Geoffrey M Prysak; Gina B Claeys; Angie S Wenzlaff; Valerie C Murphy; Fulvio Lonardo; Ann G Schwartz Journal: Carcinogenesis Date: 2008-05-02 Impact factor: 4.944
Authors: Nidra I Rodriguez; William Keith Hoots; Nadezhda V Koshkina; Jaime A Morales-Arias; Carola A Arndt; Carrie Y Inwards; Douglas S Hawkins; Mark F Munsell; Eugenie S Kleinerman Journal: J Pediatr Hematol Oncol Date: 2008-07 Impact factor: 1.289
Authors: C Mascaux; B Martin; M Paesmans; T Berghmans; M Dusart; A Haller; P Lothaire; A-P Meert; J-J Lafitte; J-P Sculier Journal: Br J Cancer Date: 2006-06-20 Impact factor: 7.640